Zealand Pharma A/S ZEAL

Ribbon cutting ceremony Officially inauguration of Zealand Pharma Research Hub in Cambridge, MA.(From left: Eric Rojas, VP, Head of Investor Relations, Zealand Pharma; Yi-An Huang, Cambridge City Manager; Christina Sonnenborg Bredal, Chief People Officer, EVP, Zealand Pharma; Sumbul Siddiqui, Mayor of Cambridge; Jesper Møller Sørensen, Danish Ambassador to the United States; Adam Steensberg, CEO and President, Zealand Pharma; Martin Nicklasson, Chair of the Board, Zealand Pharma; Utpal Singh, Ch

Zealand Pharma (ZEAL) said Thursday that Boehringer Ingelheim's survodutide achieved up to 13.1% ave

Company announcement – No. 52 / 2026 Zealand Pharma announces Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes In the SYNCHRONIZE-2 trial, which met its co-primary endpoints, participants achieved significant body weight reduction of up to 13.1% versus 3.1% in the placebo arm, after 76 weeks of treatment with survodutide in people with type 2 diabetes, a po

Company announcement – No. 51 / 2026 Total number of shares and voting rights in Zealand Pharma as of September 30, 2026 Copenhagen, Denmark, September 30, 2026 – Zealand Pharma A/S (“Zealand Pharma” or "the Company") (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announces, in accordance with section 32 of the Danish Capital Markets Act, the total number of shares and voting rights in the Company at the end of a calendar month durin

Press release – No. 18 / 2026 Zealand Pharma to present additional data from Phase 2 ZUPREME-1 trial for petrelintide at EASD 2026 and announces publication of trial results in The Lancet Diabetes & Endocrinology Treatment with petrelintide was associated with clinically meaningful, double-digit weight loss, with a gastrointestinal tolerability profile comparable to placeboTreatment was associated with significant improvements in cardiometabolic disease risk factors, including reductions in puls

Company announcement No. 50 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 39, 2026) Copenhagen, Denmark, September 28, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today reports transactions related to its share buy-back program (the “Program”) for week 39 (September 21 - September 25, 2026). The Program is carried out in accordance with Article

Press release – No. 17 / 2026 Zealand Pharma announces initiation of the registrational Phase 3 ZUPREME program of petrelintide in people with overweight or obesity The Phase 3 initiation marks a defining step toward establishing petrelintide as a future first-choice therapy for millions of people living with overweight or obesityThe global Phase 3a ZUPREME program consists of three trials, designed to support marketing applications for petrelintide monotherapy in chronic weight managementThe Ph

Company announcement No. 49 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 38, 2026) Copenhagen, Denmark, September 21, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today reports transactions related to its share buy-back program (the “Program”) for week 38 (September 14 - September 18, 2026). The Program is carried out in accordance with Article

Press release – No. 16 / 2026 Zealand Pharma receives positive CHMP opinion for Zeydovio™ (glepaglutide) for the treatment of short bowel syndrome The CHMP of the European Medicines Agency has recommended the approval of Zeydovio™ (glepaglutide) for the treatment of short bowel syndromeThe positive CHMP opinion marks the first major advancement in short bowel syndrome treatment in Europe in more than a decadeZeydovio’s™ evidenced efficacy combined with its simple delivery, positions it as a tran

Zealand Pharma (CPSE:ZEAL) has granted Elvinix an exclusive license to develop and commercialize its GLP-1/gastrin dual-agonist peptide portfolio. The agreement focuses on regenerative therapy approaches for type 1 diabetes using Zealand Pharma’s novel dual-agonist peptide candidates. Elvinix will lead clinical development and commercialization activities for these GLP-1/gastrin assets within type 1 diabetes treatment. Beyond the GLP-1/gastrin dual-agonist license for type 1 diabetes,...

DOVER, Del., September 15, 2026--Elvinix secures exclusive license to Zealand Pharma's GLP-1/gastrin dual-agonist peptides to develop a regenerative therapy for type 1 diabetes.

Company announcement No. 48 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 37, 2026) Copenhagen, Denmark, September 14, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today reports transactions related to its share buy-back program (the “Program”) for week 37 (September 7 - September 11, 2026). The Program is carried out in accordance with Article 5

Company announcement – No. 47 / 2026 Zealand Pharma increases its share capital as a result of the exercise of employee warrants Copenhagen, Denmark, September 10, 2026 – Zealand Pharma A/S (“Zealand Pharma”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a biotechnology company transforming the future of metabolic health, has by decision of the Board of Directors increased its share capital by a nominal amount of DKK 31,247 divided into 31,247 new shares with a nominal value of DKK 1 each. The capital i

Press release – No. 15 / 2026 Zealand Pharma to participate in the Morgan Stanley 24th Annual Global Healthcare Conference Copenhagen, Denmark, September 9, 2026 - Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, announced that Chief Executive Officer, Adam Steensberg, will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference in New York on Wednesday, September 16, 2026, at 11:30am

Company announcement No. 46 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 36, 2026) Copenhagen, Denmark, September 7, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today reports transactions related to its share buy-back program (the “Program”) for week 36 (August 31 - September 4, 2026). The Program is carried out in accordance with Article 5 of

Company announcement No. 45 / 2026 Correction: Zealand Pharma - Transactions related to share buy-back program (week 35, 2026) Copenhagen, Denmark, September 2, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, hereby corrects information regarding the dates for the reported transactions related to its share buy-back program (the "Program") for week 35 (August 24 – August 28, 2026)

On August 12, Royalty Pharma (NASDAQ:RPRX) agreed to pay Zealand Pharma $100 million for the rights to future royalties on rusfertide, an experimental treatment for a rare blood disorder called polycythemia vera. It is Royalty Pharma’s second collaboration with Zealand, and it arrives just as rusfertide awaits a decision from the FDA. For a company […]

Company announcement No. 44 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 35, 2026) Copenhagen, Denmark, August 31, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today reports transactions related to its share buy-back program (the “Program”) for week 35 (August 24 - August 28, 2026). The Program is carried out in accordance with Article 5 of Regu

Company announcement – No. 43 / 2026 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, August 28, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, has received information on transactions in Zealand Pharma's shares or related securities conducted by persons